[{"indications": "Indications\u00a0depressive illness", "name": "ISOCARBOXAZID ", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.3 Antidepressant drugs", "4.3.2 Monoamine-oxidase inhibitors", "ISOCARBOXAZID"], "cautions": "Cautions\u00a0see under Phenelzine", "side-effects": "Side-effects\u00a0see under Phenelzine", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3345.htm", "doses": ["Initially 30\u00a0mg daily in single or divided doses until\r\nimprovement occurs (increased after 4 weeks if necessary to max. 60\u00a0mg\r\ndaily for 4\u20136 weeks under close supervision), then reduced to usual\r\nmaintenance dose 10\u201320\u00a0mg daily (but up to 40\u00a0mg daily may be required); elderly 5\u201310\u00a0mg daily; child not recommended"], "pregnancy": "Pregnancy\u00a0\n(From 4.3.2 Monoamine-oxidase inhibitors: British National Formulary)\nPregnancy\u00a0There is an increased risk of neonatal malformations when phenelzine, isocarboxazid, or tranylcypromine is used during pregnancy. The safety of moclobemide in pregnancy has not been established. Manufacturers advise avoid use unless there are compelling reasons."}]